Fig. 2
From: Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
Blockade of VEGFR3 synergizes with docetaxel to reduce tumor growth and docetaxel-enhanced metastasis in 4T1 breast cancer. a Top panel, Representative images of 4T1 breast tumor cells (red) in the inguinal lymph nodes of mice treated with systemic docetaxel, 8 mg/kg IV (or vehicle control) and/or anti-VEGFR3 antibody, 400 μg total over 2 doses, IP (or control IgG) as detected by histological analysis of RFP-expressing tumor cells. Scale bar = 500 μm. Bottom panel, magnified images from boxed regions in top panel. Dotted white lines outline lymph node border. Scale bar = 100 μm. b Quantification of lymph node metastasis from whole lymph node scans as percent coverage of RFP+ area in whole lymph node sections. (n ≥ 4/group) (c) Tumor volume of treated mice (mm3) of 4T1 mice treated as described above via caliper measurements. Blue dashed arrow indicates dosing of anti-VEGFR3 antibody or control IgG and red dashed arrow indicates dosing of docetaxel or vehicle control. Curve was analyzed by MANOVA (n = 5/group) with *p < 0.05, **p < 0.01